Evidence map›Paper›PMID 39256651›Full record

ArticleBMC infectious diseases2024

Evaluation of the mpox surveillance system in Cameroon from 2018 to 2022: a laboratory cross-sectional study.

Delia Delia Djuicy, Chanceline Ndongo Bilounga, Linda Esso, Moctar Mohamed Moulioum Mouiche, Martial Gides Wansi Yonga, Gael Dieudonné Essima, Inès Manda Emah Nguidjol, Pricilla Josephine Ambany Anya, Elisabeth Betsi Noma Dibongue, Alain Georges Mballa Etoundi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Delia Delia DjuicyVirology Service, Centre Pasteur of Cameroon, 451 Rue 2005, P. O. Box 1274, Yaoundé, Cameroon.
Chanceline Ndongo BiloungaDepartment for the Control of Disease, Epidemics and Pandemics (DLMEP), Ministry of Public Health, Yaoundé, Cameroon.
Linda EssoDepartment for the Control of Disease, Epidemics and Pandemics (DLMEP), Ministry of Public Health, Yaoundé, Cameroon.
Moctar Mohamed Moulioum MouicheUSAID's Infectious Disease Detection and Surveillance (IDDS) Program, ICF, Yaoundé, Cameroon.
Martial Gides Wansi YongaVirology Service, Centre Pasteur of Cameroon, 451 Rue 2005, P. O. Box 1274, Yaoundé, Cameroon.
Gael Dieudonné EssimaVirology Service, Centre Pasteur of Cameroon, 451 Rue 2005, P. O. Box 1274, Yaoundé, Cameroon.
Inès Manda Emah NguidjolDepartment for the Control of Disease, Epidemics and Pandemics (DLMEP), Ministry of Public Health, Yaoundé, Cameroon.
Pricilla Josephine Ambany AnyaDepartment for the Control of Disease, Epidemics and Pandemics (DLMEP), Ministry of Public Health, Yaoundé, Cameroon.
Elisabeth Betsi Noma DibongueNational Program for the Fighting Against Emerging and Re-emerging Zoonosis (PNLZER), Prime Ministry Office, Yaoundé, Cameroon.
Alain Georges Mballa EtoundiDepartment for the Control of Disease, Epidemics and Pandemics (DLMEP), Ministry of Public Health, Yaoundé, Cameroon.
Sara Irène EyangohVirology Service, Centre Pasteur of Cameroon, 451 Rue 2005, P. O. Box 1274, Yaoundé, Cameroon.
Mirdad KazanjiVirology Service, Centre Pasteur of Cameroon, 451 Rue 2005, P. O. Box 1274, Yaoundé, Cameroon.
Richard NjouomVirology Service, Centre Pasteur of Cameroon, 451 Rue 2005, P. O. Box 1274, Yaoundé, Cameroon. njouom@pasteur-yaounde.org.

Funding

The U.S. Agency for International Development (USAID) /Infectious Disease Detection and Surveillance (IDDS) Project GS00Q14OADU119
6 · The paper itself

Abstract

backgroundFormal assessment of a surveillance system's features and its ability to achieve objectives is crucial for disease control and prevention. Since the implementation of the mpox surveillance system in Cameroon, no evaluation has been conducted.

methodsIn a cross-sectional study, we assessed the performance of the mpox surveillance system in accordance with the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) guidelines. We collected mpox surveillance data from 2018 to 2022 and conducted a survey with key stakeholders of the surveillance program. The survey results were summarized. The rates of complete reporting and mpox detection, as well as the time lag between the different stages of surveillance were analyzed using R version 4.1.

resultsThe mpox detection rate was 21.6% (29/134) over the five years under review. Surveillance indicators revealed that a combination of sample types, including vesicles, crust, and blood, was associated with higher case confirmation. Overall, the mpox surveillance system was effective. Weaknesses in terms of simplicity were identified. Most components of the assessed system failed to meet the timeliness and data quality goals, except for the laboratory component, which was commendable. The lack of a computerized shared database and the system's non-sustainability were a course of concern.

conclusionsDespite all identified bottlenecks in the mpox surveillance system in Cameroon, it was found to meet it stipulated goals. Recommendations are made for training on surveillance system features, particularly at the facility/field level. Therefore, there is a crucial need to globally improve the mpox surveillance system in Cameroon for better disease control.

Indexed as

Mpox, MonkeypoxWorld Health OrganizationCameroonCross-Sectional StudiesHumansAttributesCameroonDisease controlMpoxSurveillanceSurveillance stepsSurveillance system

Identifiers

PMID39256651
PMCPMC11385501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.